FDA approves Astellas injectable antifungal drug for newborns

Injectable antifungal drug

The FDA has approved the first antifungal drug to specifically treat invasive candidiasis in newborns.

From Astellas, the new drug for injection micafungin (Mycamine) was approved to treat multiple different conditions including: bloodstream infection, candidemia, acute disseminated candidiasis, candida peritonitis, abscesses without meningoencephalitis and/or ocular dissemination in infants younger than 4 months of age.

read more

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.